MRS 1220 is a highly potent and selective human Adenosine A3-R antagonist.
ChEBI: N-[9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide is a member of quinazolines.
A potent and highly selective antagonist at the human A 3 adenosine receptor (K i values are 0.65, 305, and 52 nM at hA 3 , rA 1 and rA 2A respectively. Displays an IC 50 value > 1 μ M for inhibition of binding to rat A 3 receptors).
MRS1220 (0.15 mg/kg; intraperitoneal inoculation) reduces tumor size and blood vessel formation in vivo. MRS1220 exhibits a strong in vivo anti-angiogenic effect[2].
| Animal Model: | Eight, 8 week-old male Sprague-Dawley rats bearing C6 (GSCs)[2] |
| Dosage: | 0.15 mg/kg/72 h |
| Administration: | Administered by intraperitoneal inoculation, for fifteen days |
| Result: | A reduction close to 80% and 90% in tumor volume compared to the vehicle-treated group at day ten and fifteen post-treatment, respectively.
|
